QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lam, J. L. Articles by Benet, L. Z. Search for Related Content PubMed PubMed Citation Articles by Lam, J. L. Articles by Benet, L. Z.

HEPATIC MICROSOME STUDIES ARE INSUFFICIENT TO CHARACTERIZE IN VIVO HEPATIC METABOLIC CLEARANCE AND METABOLIC DRUG-DRUG INTERACTIONS: STUDIES OF DIGOXIN METABOLISM IN PRIMARY RAT HEPATOCYTES VERSUS MICROSOMES

Department of Biopharmaceutical Sciences, University of California, San Francisco

The effects of hepatic uptake and efflux transporters on metabolism of digoxin were examined in isolated rat hepatocytes versus microsomes. The metabolic clearance estimated from microsomes was 4.59 ± 0.69 ml/min/kg. However, the metabolic clearance estimated from hepatocytes was 15.9 ± 3.0 ml/min/kg. The former did not correlate with in vivo clearance (12.9 ml/min/kg) for digoxin. Rifampin (an organic anion-transporting peptide 2 inhibitor) or GG918 [GF120918 (N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide)] (a potent P-glycoprotein inhibitor) were used to estimate effects of uptake or efflux transporters on digoxin metabolism. Whereas both inhibitors exerted minimal effects on metabolism in microsomes, rifampin and GG918 significantly decreased and increased digoxin metabolism in hepatocytes, respectively. Concentration-time course studies further demonstrated that, compared with the area under the curve (AUC) of control (15.6 ± 0.1 µM · min), an increase of AUC (20.1 ± 0.5 µM · min, p < 0.005) was observed when digoxin was coincubated with rifampin and a decrease of AUC (14.1 ± 0.1 µM · min, p < 0.01) when GG918 was also present. Digoxin primary metabolite concentrations changed directionally in an inverse manner with parent drug concentrations, as would be expected. These results strongly suggest that the hepatic uptake and efflux transporters that are found in hepatocytes, but not in microsomes, modulate intracellular concentration of digoxin and thus affect metabolism. We conclude that the interplay of transporters and enzymes must be considered in defining the intrinsic metabolic clearance of the liver and in evaluating potential drug-drug interactions.

This article has been cited by other articles:

				A. J. Parker and J. B. Houston Rate-Limiting Steps in Hepatic Drug Clearance: Comparison of Hepatocellular Uptake and Metabolism with Microsomal Metabolism of Saquinavir, Nelfinavir, and Ritonavir Drug Metab. Dispos., July 1, 2008; 36(7): 1375 - 1384. [Abstract] [Full Text] [PDF]

				X. Tian, M. J. Zamek-Gliszczynski, J. Li, A. S. Bridges, K.-i. Nezasa, N. J. Patel, T. J. Raub, and K. L. R. Brouwer Multidrug Resistance-Associated Protein 2 Is Primarily Responsible for the Biliary Excretion of Fexofenadine in Mice Drug Metab. Dispos., January 1, 2008; 36(1): 61 - 64. [Abstract] [Full Text] [PDF]

				D. A. J. Bow, J. L. Perry, D. S. Miller, J. B. Pritchard, and K. L. R. Brouwer Localization of P-gp (Abcb1) and Mrp2 (Abcc2) in Freshly Isolated Rat Hepatocytes Drug Metab. Dispos., January 1, 2008; 36(1): 198 - 202. [Abstract] [Full Text] [PDF]

				D. Hallifax and J. B. Houston Saturable Uptake of Lipophilic Amine Drugs into Isolated Hepatocytes: Mechanisms and Consequences for Quantitative Clearance Prediction Drug Metab. Dispos., August 1, 2007; 35(8): 1325 - 1332. [Abstract] [Full Text] [PDF]

				N. F. Smith, F. I. Raynaud, and P. Workman The application of cassette dosing for pharmacokinetic screening in small-molecule cancer drug discovery Mol. Cancer Ther., February 1, 2007; 6(2): 428 - 440. [Abstract] [Full Text] [PDF]

				D. Hallifax and J. B. Houston Uptake and Intracellular Binding of Lipophilic Amine Drugs by Isolated Rat Hepatocytes and Implications for Prediction of in Vivo Metabolic Clearance Drug Metab. Dispos., November 1, 2006; 34(11): 1829 - 1836. [Abstract] [Full Text] [PDF]

				J. L. Lam, S. B. Shugarts, H. Okochi, and L. Z. Benet Elucidating the Effect of Final-Day Dosing of Rifampin in Induction Studies on Hepatic Drug Disposition and Metabolism J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 864 - 870. [Abstract] [Full Text] [PDF]

				J. L. Lam, H. Okochi, Y. Huang, and L. Z. Benet IN VITRO AND IN VIVO CORRELATION OF HEPATIC TRANSPORTER EFFECTS ON ERYTHROMYCIN METABOLISM: CHARACTERIZING THE IMPORTANCE OF TRANSPORTER-ENZYME INTERPLAY Drug Metab. Dispos., August 1, 2006; 34(8): 1336 - 1344. [Abstract] [Full Text] [PDF]

				Y. Huang, H. Okochi, B. C. H. May, G. Legname, S. B. Prusiner, L. Z. Benet, B. J. Guglielmo, and E. T. Lin QUINACRINE IS MAINLY METABOLIZED TO MONO-DESETHYL QUINACRINE BY CYP3A4/5 AND ITS BRAIN ACCUMULATION IS LIMITED BY P-GLYCOPROTEIN Drug Metab. Dispos., July 1, 2006; 34(7): 1136 - 1144. [Abstract] [Full Text] [PDF]

				Y. Y. Lau, H. Okochi, Y. Huang, and L. Z. Benet PHARMACOKINETICS OF ATORVASTATIN AND ITS HYDROXY METABOLITES IN RATS AND THE EFFECTS OF CONCOMITANT RIFAMPICIN SINGLE DOSES: RELEVANCE OF FIRST-PASS EFFECT FROM HEPATIC UPTAKE TRANSPORTERS, AND INTESTINAL AND HEPATIC METABOLISM Drug Metab. Dispos., July 1, 2006; 34(7): 1175 - 1181. [Abstract] [Full Text] [PDF]

				Y. Y. Lau, H. Okochi, Y. Huang, and L. Z. Benet Response to Comments on "Multiple Transporters Affect the Disposition of Atorvastatin and Its Two Active Hydroxy Metabolites: Application of in Vitro and ex Situ Systems" J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1387 - 1387. [Full Text] [PDF]

				Y. Y. Lau, H. Okochi, Y. Huang, and L. Z. Benet Multiple Transporters Affect the Disposition of Atorvastatin and Its Two Active Hydroxy Metabolites: Application of in Vitro and ex Situ Systems J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 762 - 771. [Abstract] [Full Text] [PDF]

				P. Zhao, K. L. Kunze, and C. A. Lee EVALUATION OF TIME-DEPENDENT INACTIVATION OF CYP3A IN CRYOPRESERVED HUMAN HEPATOCYTES Drug Metab. Dispos., June 1, 2005; 33(6): 853 - 861. [Abstract] [Full Text] [PDF]

				L. Z. Benet There Are No Useful CYP3A Probes that Quantitatively Predict the In Vivo Kinetics of Other CYP3A Substrates and No Expectation that One Will Be Found Mol. Interv., April 1, 2005; 5(2): 79 - 83. [Abstract] [Full Text] [PDF]

				H. Sun, Y. Huang, L. Frassetto, and L. Z. Benet EFFECTS OF UREMIC TOXINS ON HEPATIC UPTAKE AND METABOLISM OF ERYTHROMYCIN Drug Metab. Dispos., November 1, 2004; 32(11): 1239 - 1246. [Abstract] [Full Text] [PDF]